相似文献
1
Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.
Antimicrob Agents Chemother. 2001 Feb;45(2):621-3. doi: 10.1128/AAC.45.2.621-623.2001.
2
Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.
Clin Infect Dis. 2001 May 1;32(9):1373-5. doi: 10.1086/319986. Epub 2001 Apr 9.
3
Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection.
Transpl Infect Dis. 2004 Sep;6(3):117-9. doi: 10.1111/j.1399-3062.2004.00059.x.
4
Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium.
Clin Infect Dis. 2002 May 15;34(10):1412-4. doi: 10.1086/340265. Epub 2002 Apr 23.
5
Short course of linezolid treatment for vancomycin-resistant Enterococcus faecium meningitis.
Int J Clin Pract. 2006 Jun;60(6):740-1. doi: 10.1111/j.1368-5031.2006.00706.x.
6
Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid.
Pediatr Infect Dis J. 2003 Dec;22(12):1101-3. doi: 10.1097/01.inf.0000101784.83146.0c.
7
Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.
N Engl J Med. 2002 Mar 14;346(11):867-9. doi: 10.1056/NEJM200203143461121.
8
[Linezolid for the treatment of newborns infected with vancomycin-resistant Enterococcus faecium].
Rev Argent Microbiol. 2009 Jan-Mar;41(1):34-8.
9
Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature.
Clin Infect Dis. 2001 Aug 15;33(4):477-82. doi: 10.1086/321896. Epub 2001 Jul 11.
10
Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype.
J Antimicrob Chemother. 2008 Apr;61(4):838-44. doi: 10.1093/jac/dkn025. Epub 2008 Jan 29.
引用本文的文献
1
Successful Treatment of Infective Endocarditis With Oral Antibiotics: A Case Report.
Cureus. 2023 Aug 15;15(8):e43514. doi: 10.7759/cureus.43514. eCollection 2023 Aug.
2
Clinical update on linezolid in the treatment of Gram-positive bacterial infections.
Infect Drug Resist. 2012;5:87-102. doi: 10.2147/IDR.S25890. Epub 2012 Jun 25.
3
Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study.
Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2567-74. doi: 10.1007/s10096-012-1597-7. Epub 2012 Mar 20.
4
Medical treatment of endocarditis.
Curr Infect Dis Rep. 2007 Jul;9(4):271-82. doi: 10.1007/s11908-007-0043-y.
5
Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.
Antimicrob Agents Chemother. 2006 Feb;50(2):654-7. doi: 10.1128/AAC.50.2.654-657.2006.
6
Fsr-independent production of protease(s) may explain the lack of attenuation of an Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis.
Infect Immun. 2005 Aug;73(8):4888-94. doi: 10.1128/IAI.73.8.4888-4894.2005.
7
Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.
Curr Infect Dis Rep. 2005 Jul;7(4):245-250. doi: 10.1007/s11908-005-0055-4.
8
Occurrence of MRSA endocarditis during linezolid treatment.
Eur J Clin Microbiol Infect Dis. 2003 Jun;22(6):372-3. doi: 10.1007/s10096-003-0959-6. Epub 2003 May 27.
本文引用的文献
1
Linezolid therapy of Staphylococcus aureus experimental osteomyelitis.
Antimicrob Agents Chemother. 2000 Dec;44(12):3438-40. doi: 10.1128/AAC.44.12.3438-3440.2000.
2
Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
Clin Infect Dis. 2000 Jan;30(1):146-51. doi: 10.1086/313597.
3
Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1999 Dec;43(12):2873-6. doi: 10.1128/AAC.43.12.2873.
4
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.
J Antimicrob Chemother. 1999 Aug;44(2):251-61. doi: 10.1093/jac/44.2.251.
5
In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1999 Jun;34(2):119-22. doi: 10.1016/s0732-8893(99)00016-4.
6
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
Antimicrob Agents Chemother. 1999 Jan;43(1):115-20. doi: 10.1128/AAC.43.1.115.
7
Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
Clin Infect Dis. 1998 Dec;27(6):1554-6. doi: 10.1086/517755.
8
In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1998 Feb;30(2):89-92. doi: 10.1016/s0732-8893(97)00207-1.
9
Multiplex PCR detection of vanA, vanB, vanC-1, and vanC-2/3 genes in enterococci.
J Clin Microbiol. 1997 Mar;35(3):703-7. doi: 10.1128/jcm.35.3.703-707.1997.
10
Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.
Clin Infect Dis. 1997 Jan;24(1):90-1. doi: 10.1093/clinids/24.1.90.
Zotero 插件